CSPG4 and melanoma: One of the first studies investigating the potential of anti-CSPG4 CAR T cells showed in vitro cytolytic potency against a variety of solid tumor cell lines including breast cancer, melanoma, mesothelioma, glioblastoma and osteosarcoma (103).